Natural Capsules Q2 FY26 Earnings Analysis
Published 5 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹154 Cr
Price
₹147
Market Cap
₹154 Cr
How does Natural Capsules rank in Pharmaceuticals & Biotechnology?
Compare Natural Capsules against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Natural Capsules — Quarterly revenue & net profit
Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Reported quarterly figures (₹ Cr). Latest: revenue ₹58 Cr, net profit ₹-5 Cr.
Full financials →Earnings Summary
Capsule business topline expected to reach Rs. Capsule business topline expected to reach Rs.
📊 Revenue & Sales Performance
- →Capsule business topline expected to reach Rs. 235-240 crores with current and upcoming capacity expansions (Page 19, 21).
- →Capsule segment growing consistently at about 6% annually in India and 4% internationally (Page 16).
- →HPMC capsule sales are targeted to increase, potentially raising EBITDA margins to 16%-18%, and eventually aiming for 20% with capacity utilization improvements (Page 22, 16).
- →Exports and substitution of low-end customers with higher-value clients expected to drive revenue growth beyond industry average (Page 16).
- →API division aims for Rs. 40 crores revenue in FY’26 but is currently facing technical challenges limiting growth; potential to scale after resolving fermentation yield issues (Pages 9, 15).
- →Overall FY'26 topline projected around Rs. 225 crores considering tariff impacts and execution delays (Page 5).
- →Long-term strategy focuses on capacity utilization, increased exports, R&D, and improving operational efficiencies to achieve growth.
📈 Profitability & Margins
- →Capsule business topline expected to reach Rs. 235-240 crores with EBITDA margins improving to 16%-18% in coming quarters as additional HPMC lines commission.
- →Gradual margin improvement anticipated beyond 20% by replacing low-end customers with higher value international clients.
- →API division targeting Rs. 40 crores revenue in FY'26 but currently facing technical scale-up issues; cash breakeven expected at around Rs. 100 crores revenue with 7%-8% EBITDA margin.
- →Overall FY'26 topline now estimated around Rs. 225 crores, lower than earlier guidance of Rs. 270-280 crores, primarily due to US tariff impact and delayed capacity utilization.
- →Management hopeful for resolution of tariff issues by end of 2025 and government consideration for PLI incentive timeline extension, which could aid profitability.
- →Long-term strategy remains intact, expecting growth and profitability to resume once external hurdles are cleared.
🏗️ Capital Expenditure Plans
- Natural Capsules is progressing confidently with its capital expenditure program.
- The new HPMC production line is on schedule for commissioning by the end of Q2 FY'26.
- This capacity addition aims to fulfill growing customer demand for different capsule sizes and increase export volumes once tariff issues clarify.
- The company plans to convert some gelatin capsule lines into HPMC lines if demand further increases.
- Competitors like ACG and Healsee Group are investing $100 million and $70 million respectively in US-based HPMC capsule plants, which will take time; by then, market demand is expected to rise.
- For the API division, there are no immediate new capex plans mentioned, but focus is on resolving technical challenges and ramping up commercial production.
- The company may explore contract manufacturing to utilize spare API capacity in the interim.
Overall, capex is primarily focused on expanding and commissioning HPMC capsule capacity in the near term.
💰 Fundraising & Capital Structure
The transcript on the provided pages does not explicitly mention any current or planned future fundraising through debt or equity by Natural Capsules Limited. Key points related to financials and operational challenges include:
- The company has an equity base of about Rs. 120 crores for the API subsidiary.
- There is no specific mention of fresh debt or equity fundraising plans in the discussion.
- The management is focused on resolving operational issues, improving capacity utilization, and scaling up production.
- Possible strategic decisions such as demerger or bringing in strategic partners for API would be considered by the board as needed, but no current decision on fundraising has been disclosed.
- The company’s strategy currently revolves around operational execution and growth rather than raising capital.
Hence, as per the transcript, there are no disclosed plans for new fundraising through debt or equity at this time.
📋 Order Book & Pipeline
- →The transcript does not explicitly mention the exact current or expected order book or pending orders in numeric detail.
- →There is discussion about demand and volume recovery, especially in the US and other international markets, with some slowdowns due to tariffs and regulatory issues.
- →The Mexico export order is ongoing but volumes are below expectations.
- →Distributors remain confident of demand recovery despite tariff challenges.
- →The company is commissioning new HPMC lines to meet customer demand.
- →Backup plans include converting HPMC capacity to gelatin capsules if needed.
- →Overall, while challenges have caused delays or slowed orders, the company expects demand to improve once tariff and regulatory issues resolve.
Key Metrics
Frequently Asked Questions
What were Natural Capsules Q2 FY26 results?
Capsule business topline expected to reach Rs. Capsule business topline expected to reach Rs.
What is Natural Capsules share price analysis?
Natural Capsules currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹154 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules planning capital expenditure?
Natural Capsules is progressing confidently with its capital expenditure program.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.